Neuroprotective products are medications that protect the brain neurons from degeneration and injury. These products are used in the treatment of several central nervous system complications such as Parkinson's disease, Alzheimer's disease, and traumatic brain injuries among others. Neurodegenerative diseases and their prevalence increases significantly with age. Hence, the demand for neuroprotectives would increase in the future, as average life spans are increasing, which opens up a huge market for novel drugs for the treatment of these diseases. The drivers for this market are the increasing incidence and prevalence of neurodegenerative diseases, especially in aging populations and a need for the treatment of brain injuries caused chiefly by road accidents. However, high costs involved in research and development, strict regulatory approvals and the high failure rate of majority of the prospective drugs in clinical trials would restrict growth in this market. With the high prevalence rates of neurogenerative disease and the lack of specific treatment options, the opportunities are tremendous for the entry of novel drugs.
Neuroprotective Products Market by Class of Drugs
The neuroprotective drugs are Cholinesterase inhibitors, NMDA receptor antagonists, Ion channel modulators, Anti-inflammatory and anti-apoptotic agents, Mitochondrial dysfunction regulators Neurotropic factors, Anti excitotoxic agents , Ion channel modulators, Metal Ion Chelators Free radical trappers, and others.
The Cholinesterase inhibitors and NMDA receptor antagonists are used to treat Alzheimers. As the disease burden is high for this ailment, these drugs would command a major market share. However, the opportunity for emerging drugs is high, as CNS disorders involve an interplay of highly complex and multi- factorial processes & pathways. Therefore, investment in research and development would have high pay offs.
Neuroprotective Products Market by use in the treatment of Medical Conditions
The neuroprotective drugs are used in the treatment of Alzheimer's disease, Multiple sclerosis, Parkinson's disease, Brain injury, Huntington's disease, Retinal disorders, Amyotrophic lateral sclerosis (ALS), Neuropathies, and other disorders affecting the nervous system.
According to the Alzheimer's association, an estimated 5.2 million Americans have Alzheimer's and it is the 6th leading cause of death accounting for the death of more than 500,000 persons per year in the United States. Hence, the market for treatment of Alzheimers is huge and it would spur the development of neuroprotective drugs.
Neuroprotective Market by Geography
The market is segmented by geography into North America, Europe, Asia Pacific and RoW. In the United States, death due to Alzheimers increased by 68 percent during 2000 to 2010. According to the Parkinson Disease foundation, 60,000 Americans are diagnosed of Parkinsons each year. Hence, North America is the major market for these products. World –wide, an estimated five to seven million people are living with Parkinson disease, which would increase the demand for neuroprotective drugs and spur research and development. Europe and Asia Pacific would also see an increased demand as the cases for neurodegenerative diseases increases in these regions.
Competitive Analysis
Genervon Biopharmaceuticals, NeuroVive Pharmaceutical,Ceregene, BHRPharma LLC, Neuren Pharmaceuticals, Allon therapeutics, Inc., Bionure Inc. are some of the key players in this market. In 2013, Bionure and The Myelin Repair Foundation (MRF) entered into a collaborative partnership agreement with the aim of advancing development of therapeutics for multiple sclerosis. This partnership would enable the commercialization of many promising compounds for the treatment of multiple sclerosis.
High Level Analysis
An overview of the neuroprotective market by segmentation of the market by type, application and geography, identifies the opportunities as well as associated risks in this market. Porter’s five force model analyzes the bargaining power of the supplier and buyer as well as the threat posed by substitutes and new entrants which would enable a deeper understanding of changing market dynamics. The report helps to identify market leaders and the strategic business decisions taken by them. The impact of drivers, restraints and opportunities and other market dynamics are described in detail.
KEY BENEFITS
- Competitive analysis of companies and policies adopted by competitors would help in making strategic decisions
- In-depth analysis of current market scenario would help in understanding opportunities in this market
- Segmentation based on applications would help in understanding future growth prospects and areas where investments can be made.
- Analysis of drivers and restrains focuses on the opportunities and risks of this market, which would enable decision-making
- Estimations of growth in this market based on upcoming drugs would give an overall idea of areas of growth to stakeholders.
Neuroprotective Products Market, by Class of Drugs Report Highlights
| Aspects | Details |
 By Class of Drugs |
|
 By use in the treatment of Medical Conditions |
|
 By Geography |
|
 Key Market Players | Novartis AG, Teva Pharmaceuticals, UCB S.A., GlaxoSmithKline plc, Merck & Co., Inc., Athersys Inc., Baxter International Inc., Pfizer Inc., Biogen Inc., Avanir Pharmaceuticals Inc. |
Loading Table Of Content...
